지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제11호
- 발행연도
- 2015.1
- 수록면
- 4,769 - 4,775 (7page)
이용수
초록· 키워드
오류제보하기
Background: Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and thirdly leading cause of cancer-related death worldwide. The estimated risk of hepatocellular carcinoma is 15 to 20 times as high among persons infected with HCV as it is among those who are not infected, with most of the excess risk limited to those with advanced hepatic fibrosis or cirrhosis. Glypican3 (GPC3) plays a key role in relation to signaling with growth factors, regulating the proliferative activity of cancer cells. Glutamine synthetase (GS) catalyzes the synthesis of glutamine from glutamate and ammonia in the mammalian liver. GS was suggested as a specific marker for tracing cell lineage relationships during hepatocarcinogenesis. In normal liver, GS expression is seen in pericentral hepatocytes, but not by midzonal or periportal hepatocytes. In HCC, strong and diffuse GS expression in seen in tumor cells. Results: Glypican3 immunopositvity was highly specific and sensitive indicator for hepatocellular carcinoma as well as glutamine synthetase which was found to be a sensitive and specific indicator for development of hepatocellular carcinoma when compared to cirrhosis, liver cell dyspalsia and metastatic carcinomas. Statistical analysis revealed a significant association between GPC3 and GS with tumor size (P=0.003, p=0.006, respectively). Diffuse staining significantly associated with large tumor size while, focal and mixed staining was detected more with small tumor size. Studying the relation with tumor grade also revealed significant association between diffuse GPC3 and GS staining with high tumor grade. Diffuse staining was detected in 91.7% and 100% respectively of poorly differentiated specimens and only in 33.3% and 22.2% of well differentiated specimens. Conclusions: While using GPC3 and GS to screen for premalignant hepatic lesions remains controversial, our data suggest that GPC3 and GS may be a reliable diagnostic immunomarkers to distinguish HCC from benign hepatocellular lesions. However, negative immunostaining should not exclude the diagnosis of HCC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis
Clinical and Molecular Hepatology
2016 .01
-
Systemic therapy in advanced hepatocellular carcinoma
Clinical and Molecular Hepatology
2023 .04
-
A combined large-cell neuroendocrine carcinoma and hepatocellular carcinoma tumor in the liver: A rare case report
Annals of Hepato-Biliary-Pancreatic Surgery
2022 .12
-
Role of Surgery in Stage IV Hepatocellular Carcinoma (HCC)
대한임상종양학회 학술대회지
2015 .02
-
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Clinical and Molecular Hepatology
2023 .04
-
Advances in Management of Hepatocellular Carcinoma
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Clinical and Molecular Hepatology
2023 .01
-
Hepatocellular Carcinoma Arising from Hepatocellular Adenoma in an Elderly Male Patient
Journal of Liver Cancer
2021 .01
-
The development of alcohol-associated hepatocellular carcinoma mouse model
한국실험동물학회 학술발표대회 논문집
2022 .07
-
Surveillance for hepatocellular carcinoma: It is time to move forward
Clinical and Molecular Hepatology
2022 .10
-
How long should physicians follow up with patients after curative treatment for hepatocellular carcinoma?
Clinical and Molecular Hepatology
2020 .01
-
Arginase-1 and P-glycoprotein are downregulated in canine hepatocellular carcinoma
Journal of Veterinary Science
2021 .09
-
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
Clinical and Molecular Hepatology
2023 .04
-
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Clinical and Molecular Hepatology
2023 .04
-
Long-term Survival of a Patient with a Large Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis and Spontaneous Tumor Rupture
Journal of Liver Cancer
2020 .01
-
Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
Clinical and Molecular Hepatology
2023 .01
-
Discrepancy between the Actual Clinical Status of Patients with Hepatocellular Carcinoma and Expectations from Hepatocellular Carcinoma Surveillance: a Single-Center Study
Journal of Liver Cancer
2019 .01
-
A Case of Lymphocyte-Rich Hepatocellular Carcinoma in a Patient Who Was Treated for Colon Cancer
Journal of Liver Cancer
2021 .01
-
Can hepatocellular carcinoma recurrence be prevented after liver transplantation?
Clinical and Molecular Hepatology
2021 .10
-
Establishment of an optimal orthotopic rat hepatocellular carcinoma model using N1-S1 cells
한국실험동물학회 학술발표대회 논문집
2022 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0